Comparing the current results to its competitors, Azitra Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.95 %, recorded in the same quarter.
Azitra Inc , slower than the average decrease reported by the company's competitors of -55.9 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -55.9 %
Azitra Inc 's Comment on Competition and Industry Peers
The company operates in the highly competitive biopharmaceutical industry, characterized by rapidly advancing technologies and a focus on proprietary drugs. It faces competition from other biopharmaceutical companies, academic institutions, governmental agencies, and public and private research institutions. In the area of Netherton syndrome, no FDA-approved drug currently exists. Standard care consists of skin cleansing and moisturizers, though some treatments have limited tolerability. MatriSys is developing Netherton syndrome programs at a preclinical stage. Competitors may develop safer, more effective, or more convenient drugs and may obtain regulatory approvals more quickly, potentially establishing strong market positions before the company. Many competitors possess significantly greater financial resources and expertise in drug development and commercialization. Additionally, mergers and acquisitions within the pharmaceutical and biotechnology industries may increase competition.
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
Sources:
Azitra Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Azitra Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
